Year 2019 / Volume 111 / Number 9
Letter
The onset of ulcerative colitis during treatment with secukinumab: can anti-IL-17A be a trigger for inflammatory bowel disease?

720-721

DOI: 10.17235/reed.2019.5841/2018

Rafael Rodríguez Moncada, Juan María Vázquez Morón, Héctor Pallarés Manrique,

Abstract
In recent months, cases of IBD have been reported in the context of treatment with secukinumab, a monoclonal antibody that blocks IL-17A and which is used in the treatment of certain rheumatic disorders. We present a case of a patient with psoriatic arthritis, with a first-degree relative who had suffered ulcerative colitis, who presented with onset ulcerative colitis in the weeks following treatment initiation with this drug.
Share Button
New comment
Comments
No comments for this article
References
Fobelo Lozano MJ, Serrano Giménez R, Castro Fernández M. Emergence of Inflammatory Bowel Disease During Treatment with Secukinumab. J Crohns Colitis. 2018 May 9. doi: 10.1093/ecco-jcc/jjy063.
Abraham C, Dulai PS, Vermeire S et al. Lessons Learned From Trials Targeting Cytokine Pathways in Patients With Inflammatory Bowel Diseases. Gastroenterology 2017; 152(2): 374–88. doi: 10.1053/j.gastro.2016.10.018.
Ungaro R, Mehandru S, Allen PB et al. Ulcerative colitis. Lancet 2017; 389: 1756–70. doi: 10.1016/S0140-6736(16)32126-2.
Wang J, Bhatia A, Krugliak Cleveland N et al. Rapid Onset of Inflammatory Bowel Disease after Receiving Secukinumab Infusion. ACG Case Rep J 2018. doi: 10.14309/crj.2018.56.
Ehrlich D, Jamaluddin N, Pisegna J et al. A Challenging Case of Severe Ulcerative Colitis following the Initiation of Secukinumab for Ankylosing Spondylitis. Case Rep Gastrointest Med 2018. doi: 10.1155/2018/9679287.
Related articles

Letter

Tofacitinib-induced eosinophilia

DOI: 10.17235/reed.2023.9831/2023

Letter

Perianal Paget’s disease

DOI: 10.17235/reed.2022.9304/2022

Letter

Chinese dragon sign of ulcerative colitis

DOI: 10.17235/reed.2022.9154/2022

Letter

Ulcerative colitis exacerbated by strongyloidiasis

DOI: 10.17235/reed.2022.9044/2022

Letter

Mesalazine induced interstitial pneumonitis in the COVID era

DOI: 10.17235/reed.2022.8635/2021

Letter

The effect of Adacolumn® on ulcerative colitis with COVID-19

DOI: 10.17235/reed.2020.7156/2020

Letter

Sweet syndrome in severe ulcerative flare

DOI: 10.17235/reed.2020.6995/2020

Letter to the Editor

Ulcerative colitis with gastric and duodenal involvement

DOI: 10.17235/reed.2017.4685/2016

Editorial

Specialist care in the management of inflammatory bowel disease

DOI: 10.17235/reed.2016.4628/2016

Original

Mercaptopurine and inflammatory bowel disease: the other thiopurine

DOI: 10.17235/reed.2016.4546/2016

Case Report

Mesalamine-induced myopericarditis - A case report

DOI: 10.17235/reed.2016.4016/2015

Citation tools
Rodríguez Moncada R, Vázquez Morón J, Pallarés Manrique H. The onset of ulcerative colitis during treatment with secukinumab: can anti-IL-17A be a trigger for inflammatory bowel disease? . 5841/2018


Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Metrics
This article has received 635 visits.
This article has been downloaded 331 times.

Statistics from Dimensions


Statistics from Plum Analytics

Publication history

Received: 24/07/2018

Accepted: 10/10/2018

Online First: 23/07/2019

Published: 05/09/2019

Article revision time: 75 days

Article Online First time: 364 days

Article editing time: 408 days


Share
This article hasn't been rated yet.
Reader rating:
Valora este artículo:




Asociación Española de Ecografía Digestiva Sociedad Española de Endoscopia Digestiva Sociedad Española de Patología Digestiva
The Spanish Journal of Gastroenterology is the official organ of the Sociedad Española de Patología Digestiva, the Sociedad Española de Endoscopia Digestiva and the Asociación Española de Ecografía Digestiva
Cookie policy Privacy Policy Legal Notice © Copyright 2023 y Creative Commons. The Spanish Journal of Gastroenterology